

#### NEUROCRITICAL CARE: FROM RESEARCH TO RECOVERY

18<sup>TH</sup> ANNUAL MEETING • SEPTEMBER 22-25, 2020 PHOENIX CONVENTION CENTER • PHOENIX, ARIZONA

NEUR CRITICAL

NEUR CRITICAL

# Multimodality Targets in Traumatic Brain Injury

Brandon Foreman MD FACNS FNCS Associate Professor, Neurology & Rehabilitation Medicine University of Cincinnati

NEUROCRITICAL CARE: FROM RESEARCH TO RECOVERY 18<sup>77</sup> ANNUAL MEETING • SEPTEMBER 22-25, 2020 PHOENIX CONVENTION CENTER • PHOENIX, ARIZONA

NEUR@CRITICAL



## **Disclosures**

Research

- NIH
  - ✓ K23NS101123 (PI: Foreman)
  - ✓ R03NS115011 (PI: Sunar)
  - ✓ EpiBioS4Rx U54 NS100064-01 (Site PI; PI: MacArthur)
- DOD
  - ✓ W81XWH-16-2-0020 (Co-I; PI: Hartings)
  - ✓ X81XWH-18-DMRDP-PTCRA (PI:
    - Moberg)
- NSF
  - ✓ IIS-1838730 (Co-I; PI: Subbian)

#### Industry

- UCB Pharma (speaking fees, consulting)
- Minnetronix, Inc (consulting)

University of CINCINNATI COLLABORATIVE FOR RESEARCH ON ACUTE NEUROLOGICAL INJURIES

brandon.foreman@uc.edu











NEUR@CRITICAL



NEUROCRITICAL CARE: FROM RESEARCH TO RECOVERY 18<sup>TH</sup> ANNUAL MEETING • SEPTEMBER 22-25, 2020 • PHOENIX, ARIZONA



		Risk Ratio	Risk Ratio
Study or Subgroup	Weight	M-H, Random, 95% CI Ye	ear M-H. Random, 95% Cl
Mauritz 2007	6.2%	0.89 [0.67, 1.20] 20	007
Shafi 2008	7.0%	1.75 [1.40, 2.19] 20	
Mauritz 2008	7.9%	1.03 [0.91, 1.17] 20	008
Griesdale 2010	2.9%	2.32 [1.17, 4.61] 20	010
Kostic 2011	4.6%	0.72 [0.45, 1.13] 20	011
Haddad 2011	3.6%	1.38 [0.78, 2.45] 20	011
Farahvar 2012	7.0%	0.59 [0.47, 0.74] 20	12
Chesnut 2012	6.4%	0.89 [0.68, 1.17] 20	012
Biersteker 2012	1.8%	0.75 [0.30, 1.91] 20	012
Gao 2012	1.3%	1.25 [0.40, 3.91] 20	112
Talving 2013	5.8%	0.61 [0.44, 0.84] 20	13
Alali 2013	8.2%	0.87 [0.81, 0.94] 20	013 -
Kim 2014	2.6%	0.47 [0.22, 0.99] 20	014
Dawes 2014	7.4%	0.67 [0.56, 0.81] 20	014
Alkhoury 2014	7.3%	0.88 [0.72, 1.07] 20	014
Alali 2015	5.5%	0.74 [0.52, 1.06] 20	
Yuan 2015	7.0%	0.80 [0.65, 1.00] 20	15
Agrawal 2015	7.5%	0.57 [0.48, 0.68] 20	15
Total (95% CI)	100.0%	0.85 [0.73, 0.98]	•
Total events			
Heterogeneity: Tau <sup>2</sup> =	0.06; Chi2	= 105.06, df = 17 (P < 0.000	001);  2 = 84%
Test for overall effect: Z = 2.26 (P = 0.02)			U.2 U.0 1 2 5

Time from Admission (to 30 days)

Propensity-matched analysis of 1327 sTBI patients (OR 0.22; 95%CI 0.15-0.35) (Ronning 2019)

Meta-analysis of studies of ICP monitoring and mortality (RR 0.85; 95%CI 0.73-0.98) (Shen 2016)



### Situational Intracranial Pressure Management: An Argument Against a Fixed Treatment Threshold

Randall M. Chesnut, MD, FCCM, FACS, FAANS<sup>1</sup>; Walter Videtta, MD<sup>2</sup>





### **Optimizing Brain Oxygen**





Figures from Ostergaard 2013







characterizes secondary brain injury Targets for management should be . individualized based on careful interpretation of integrated multimodal data



